BPL Logo Full TransparentBPL Logo Full TransparentBPL Logo Full TransparentBPL Logo Full Transparent
  • BPL Pharma Platform 4.0
  • Development Services
  • News & Insights
  • Careers
  • Contact
Contract Pharma Reports, Bright Path Labs Accepted into FDA’s Emerging Technology Program
March 19, 2020
One America Network Reports, Fixing our Dependence on China for Drug Manufacturing | Bright Path Labs
April 17, 2020
March 25, 2020

RESEARCH TRIANGLE PARK, NC  — March 25, 2020

Bright Path Laboratories, Inc. (privately held) 3-year-old startup contract manufacturer – with offices in both Charlotte and Santa Fe, N.M. – recently got a strong show of support from The U.S. Food and Drug Administration for its patented spinning-tube-in-tube (STT) continuous-flow reactor.

The agency accepted the system, the only one of its kind that manufactures active pharmaceutical ingredients (APIs), into the FDA’s Emerging Technology Program. That program promotes innovative approaches to pharmaceutical product design and manufacturing.

For the fully article from the North Carolina Biotech Center see www.ncbiotech.org/news/bright-path-laboratories-develops-new-way-produce-active-pharmaceutical-ingredients.

About Bright Path Laboratories, Inc.

Bright Path Laboratories, Inc. is a commercial stage bio-pharmaceutical manufacturing company, dedicated to developing best-in-class continuous-flow manufacturing for the pharmaceutical sector.  For more information, please visit www.brightpathlabs.com.

Safe Harbor

To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about Bright Path Pharmaceuticals’ plans, objectives, expectations and intentions with respect to cash flow requirements, future operations and products, and development activities, and other statements identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause Bright Path Pharmaceuticals’ actual results to be materially different than those expressed in or implied by Bright Path Pharmaceuticals’ forward-looking statements. For Bright Path Pharmaceuticals, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the success and design of manufacturing facilities; and Bright Path Pharmaceuticals’ need for and ability to obtain additional financing. Bright Path Pharmaceuticals undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Share

Related posts

January 28, 2021

Bright Path Labs expands Board of Directors – Marc Fasteau


Read more
October 7, 2020

How will Quartic’s partnership with Bright Path Labs expand its presence in the life sciences?


Read more
August 20, 2020

Bright Path Laboratories selects TrackWise Digital QMS


Read more

Research & Development Labs

3900 Paseo del Sol
Santa Fe, NM 87507
info@brightpathlabs.com

Manufacturing Services

150 N. Research Campus Drive
Kannapolis, NC 28081
info@brightpathlabs.com
Copyright © 2020 Bright Path Laboratories, Inc. All Rights Reserved.
  • LinkedIn
  • Twitter